+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Cholecystitis Market, By Type, By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others) By Diagnostic Procedure, By Treatment, By End User, By Region, Competition Forecast and Opportunities, 2027

  • PDF Icon

    Report

  • 113 Pages
  • September 2022
  • Region: Global
  • TechSci Research
  • ID: 5653778
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global acute cholecystitis market is projected to accomplish an extraordinary growth in the forecast period, 2023-2027 with an impressive CAGR. The market growth can be attributed to the rising instances of gall bladder stone issues. The population is now more concerned and aware of the condition and demanding efficient and effective treatment for the same thereby aiding to the growth of the global acute cholecystitis market in the upcoming five years. Moreover, rapidly increasing research and advancement in the pharmaceutical department that has effective drugs in the pipeline of market launch is further enunciating the growth factors of the global acute cholecystitis market in the next five years. Increasing geriatric population and their tendency of weaker health and poor health conditions are further aiding the growth of the market in the near future.

Health insurances, governmental schemes have made it more feasible for the patients to afford the treatments ad thus supporting the growth of the market. The market may experience a mild restraint due to health conscious consumers that have now changed food habits and are rejuvenating their bodies with healthier food.

Market Segmentation

The global acute cholecystitis market is segmented by type, cause, diagnostic procedure, treatment, end user, regional distribution, and competitional landscape. Based on type, the market is differentiated between calculous acute cholecystitis and acalculous acute cholecystitis. By cause, the market is further segmented into gall bladder stones, tumor, bile duct blockage, microbial infection, and others. Based on diagnostic procedure, the market is fragmented into ultrasonography, cholescintigraphy, CT scan, ERCP (endoscopic retrograde cholangiopancreatography), and others. By treatment the market is differentiated between surgical and non-surgical. Based on end user, the market is bifurcated into hospitals & clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Based on type, Acute Cholecystitis May Lead Market Growth

Based on type, the market is further divided between calculous acute cholecystitis and acalculous acute cholecystitis. Depending on the obstruction site the acute cholecystitis is of two types. Acute cholecystitis is a medical condition where stone-like obstructions are accumulated in the gallbladder, or the gastro-intestinal tube that connects gallbladder to the small intestine. If the obstruction is at the gall bladder duct it is termed as calculous acute cholecystitis and if the obstruction is at any other site in the gall bladder or the tube, it is termed as acalculous acute cholecystitis. Calculous acute cholecystitis is a worse condition of gall bladder condition and requires immediate attention thereby is anticipated to hold the larger market revenue shares and assert its dominance over the market segment. Acalculous acute cholecystitis is also an emergency situation but is comparatively less painful and may register significant growth in the market shares in the next five years.

Company Profile

Holding the major shares of the global acute cholecystitis market are Boston Scientific Corporation, Fresenius Kabi AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Merck & Co., Inc., Becton, Dickinson and Company, Simulab Corporation, AbbVie, Inc., Fortimedix Surgical BV, among others. Market players are actively involved in the research and technological development in the medical device and testing kit developments diagnosing the condition at an earlier stage. The advanced technology has made it possible for the healthcare industry to provide excellent healthcare services for acute cholecystitis. Further advancement would aid the market value and brand establishment in the future five years.

Years considered for this report:

  • Historical Years: 2017-2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023-2027

Objective of the Study:

  • To analyze the historical growth of the market size of global acute cholecystitis market from 2017 to 2020.
  • To estimate and forecast the market size of global acute cholecystitis market from 2021 to 2027 and growth rate until 2027.
  • To classify and forecast global acute cholecystitis market based on type, cause, diagnostic procedure, treatment, end user, regional distribution, and competitional landscape.
  • To identify dominant region or segment in the global acute cholecystitis market.
  • To identify drivers and challenges for global acute cholecystitis market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global acute cholecystitis market.
  • To identify and analyze the profile of leading players operating in global acute cholecystitis market.
  • To identify key sustainable strategies adopted by market players in global acute cholecystitis market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers, suppliers, and distributors across the country. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufactures which could not be identified due to the limitations of secondary research. The publisher analyzed the hospitals, surgical centers, distribution channels and presence of all major players across the country.

The publisher calculated the market size of global acute cholecystitis market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:

  • Hospitals, medical practitioners, end users, and other stakeholders
  • Distributers and suppliers of products and other stakeholders
  • Organizations, forums, and alliances related to acute cholecystitis
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global Acute Cholecystitis market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Acute Cholecystitis Market, By Type:

  • Calculous Acute Cholecystitis
  • Acalculous Acute Cholecystitis

Global Acute Cholecystitis Market, By Cause:

  • Gall Bladder Stones
  • Tumor
  • Bile Duct Blockage
  • Microbial Infection
  • Others

Global Acute Cholecystitis Market, By Diagnostic Procedure:

  • Ultrasonography
  • Cholescintigraphy
  • CT Scan
  • ERCP (Endoscopic Retrograde Cholangiopancreatography)
  • Others

Global Acute Cholecystitis Market, By Treatment:

  • Surgical
  • Non-Surgical

Global Acute Cholecystitis Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Global Acute Cholecystitis Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Sweden
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Bangladesh
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Chile

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global acute cholecystitis market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.



This product will be delivered within 1-3 business days.

Table of Contents


1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Acute Cholecystitis Treatment Market4. Executive Summary
5. Voice of Customer
5.1. Factors Contributing to Prevalence of Acute Cholecystitis
5.2. Prevalence of Acute Cholecystitis, By Gender
5.3. Prevalence of Acute Cholecystitis, By Age Group
5.4. Preferred choice of Treatment for Acute Cholecystitis
6. Global Acute Cholecystitis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis)
6.2.2. By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others)
6.2.3. By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP (Endoscopic Retrograde Cholangiopancreatography), Others)
6.2.4. By Treatment (Surgical v/s Non-Surgical)
6.2.5. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
6.2.6. By Company (2021)
6.2.7. By Region
6.3. Product Market Map
7. North America Acute Cholecystitis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Cause
7.2.3. By Diagnostic Procedure
7.2.4. By Treatment
7.2.5. By End User
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Acute Cholecystitis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Cause
7.3.1.2.3. By Diagnostic Procedure
7.3.1.2.4. By Treatment
7.3.1.2.5. By End User
7.3.2. Mexico Acute Cholecystitis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Cause
7.3.2.2.3. By Diagnostic Procedure
7.3.2.2.4. By Treatment
7.3.2.2.5. By End User
7.3.3. Canada Acute Cholecystitis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Cause
7.3.3.2.3. By Diagnostic Procedure
7.3.3.2.4. By Treatment
7.3.3.2.5. By End User
8. Europe Acute Cholecystitis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Cause
8.2.3. By Diagnostic Procedure
8.2.4. By Treatment
8.2.5. By End User
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. France Acute Cholecystitis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Cause
8.3.1.2.3. By Diagnostic Procedure
8.3.1.2.4. By Treatment
8.3.1.2.5. By End User
8.3.2. Germany Acute Cholecystitis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Cause
8.3.2.2.3. By Diagnostic Procedure
8.3.2.2.4. By Treatment
8.3.2.2.5. By End User
8.3.3. United Kingdom Acute Cholecystitis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Cause
8.3.3.2.3. By Diagnostic Procedure
8.3.3.2.4. By Treatment
8.3.3.2.5. By End User
8.3.4. Italy Acute Cholecystitis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Cause
8.3.4.2.3. By Diagnostic Procedure
8.3.4.2.4. By Treatment
8.3.4.2.5. By End User
8.3.5. Spain Acute Cholecystitis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Cause
8.3.5.2.3. By Diagnostic Procedure
8.3.5.2.4. By Treatment
8.3.5.2.5. By End User
8.3.6. Sweden Acute Cholecystitis Treatment Market Outlook
8.3.6.1. Market Size & Forecast
8.3.6.1.1. By Value
8.3.6.2. Market Share & Forecast
8.3.6.2.1. By Type
8.3.6.2.2. By Cause
8.3.6.2.3. By Diagnostic Procedure
8.3.6.2.4. By Treatment
8.3.6.2.5. By End User
9. Asia-Pacific Acute Cholecystitis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Cause
9.2.3. By Diagnostic Procedure
9.2.4. By Treatment
9.2.5. By End User
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Acute Cholecystitis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Cause
9.3.1.2.3. By Diagnostic Procedure
9.3.1.2.4. By Treatment
9.3.1.2.5. By End User
9.3.2. India Acute Cholecystitis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Cause
9.3.2.2.3. By Diagnostic Procedure
9.3.2.2.4. By Treatment
9.3.2.2.5. By End User
9.3.3. South Korea Acute Cholecystitis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Cause
9.3.3.2.3. By Diagnostic Procedure
9.3.3.2.4. By Treatment
9.3.3.2.5. By End User
9.3.4. Japan Acute Cholecystitis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Cause
9.3.4.2.3. By Diagnostic Procedure
9.3.4.2.4. By Treatment
9.3.4.2.5. By End User
9.3.5. Australia Acute Cholecystitis Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Cause
9.3.5.2.3. By Diagnostic Procedure
9.3.5.2.4. By Treatment
9.3.5.2.5. By End User
9.3.6. Thailand Acute Cholecystitis Treatment Market Outlook
9.3.6.1. Market Size & Forecast
9.3.6.1.1. By Value
9.3.6.2. Market Share & Forecast
9.3.6.2.1. By Type
9.3.6.2.2. By Cause
9.3.6.2.3. By Diagnostic Procedure
9.3.6.2.4. By Treatment
9.3.6.2.5. By End User
9.3.7. Bangladesh Cholecystitis Treatment Market Outlook
9.3.7.1. Market Size & Forecast
9.3.7.1.1. By Value
9.3.7.2. Market Share & Forecast
9.3.7.2.1. By Type
9.3.7.2.2. By Cause
9.3.7.2.3. By Diagnostic Procedure
9.3.7.2.4. By Treatment
9.3.7.2.5. By End User
10. South America Acute Cholecystitis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Cause
10.2.3. By Diagnostic Procedure
10.2.4. By Treatment
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Acute Cholecystitis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Cause
10.3.1.2.3. By Diagnostic Procedure
10.3.1.2.4. By Treatment
10.3.1.2.5. By End User
10.3.2. Argentina Acute Cholecystitis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Cause
10.3.2.2.3. By Diagnostic Procedure
10.3.2.2.4. By Treatment
10.3.2.2.5. By End User
10.3.3. Colombia Acute Cholecystitis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Cause
10.3.3.2.3. By Diagnostic Procedure
10.3.3.2.4. By Treatment
10.3.3.2.5. By End User
10.3.4. Chile Acute Cholecystitis Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Cause
10.3.4.2.3. By Diagnostic Procedure
10.3.4.2.4. By Treatment
10.3.4.2.5. By End User
11. Middle East and Africa Acute Cholecystitis Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Cause
11.2.3. By Diagnostic Procedure
11.2.4. By Treatment
11.2.5. By End User
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Acute Cholecystitis Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Cause
11.3.1.2.3. By Diagnostic Procedure
11.3.1.2.4. By Treatment
11.3.1.2.5. By End User
11.3.2. Saudi Arabia Acute Cholecystitis Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Cause
11.3.2.2.3. By Diagnostic Procedure
11.3.2.2.4. By Treatment
11.3.2.2.5. By End User
11.3.3. UAE Acute Cholecystitis Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Cause
11.3.3.2.3. By Diagnostic Procedure
11.3.3.2.4. By Treatment
11.3.3.2.5. By End User
11.3.4. Turkey Acute Cholecystitis Treatment Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Type
11.3.4.2.2. By Cause
11.3.4.2.3. By Diagnostic Procedure
11.3.4.2.4. By Treatment
11.3.4.2.5. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2. Company Profiles (SWOT Analysis of Top 5 Players Profiled)
14.2.1. Boston Scientific Corporation
14.2.2. Fresenius Kabi AG
14.2.3. Pfizer Inc
14.2.4. Teva Pharmaceutical Industries Ltd.
14.2.5. Glenmark Pharmaceuticals Limited
14.2.6. Merck & Co., Inc.
14.2.7. Becton, Dickinson, and Company
14.2.8. Simulab Corporation
14.2.9. AbbVie, Inc.
14.2.10. Fortimedix Surgical BV
15. Strategic Recommendations

Companies Mentioned

  • Boston Scientific Corporation
  • Fresenius Kabi AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Becton, Dickinson and Company
  • Simulab Corporation
  • AbbVie, Inc.
  • Fortimedix Surgical BV